Originally approved by the FDA in 1999 for the treatment of low myopia ranging between –1 D to –3 D sphere, Intacs segments, now from CorneaGen, were granted a humanitarian device exemption in July 2004 for the treatment of keratoconus, for which they are primarily used today alone and/or in conjunction with collagen cross-linking technology.
A 2007 retrospective evaluation of my Intacs data with 3- to 10-year minimum follow-up in 50 eyes was recently presented at the inaugural Cornea360 meeting in Scottsdale, Arizona. Interestingly, all patients in 2007 underwent the original
Uncategorized